TP53 and cancer: This evidence is supported by recent data presented at the 2013 European Cancer Congress on neoadjuvant cetuximab-containing chemoradiotherapy (CRT) in locally advanced rectal cancer: translational data from a subgroup of patients (n = 144) treated within the EXPERT-C trial showed that the TP53 mutation status might serve as an independent predictive biomarker for cetuximab efficacy[24].